Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 trial ...
Although the Sultanate of Oman has a relatively low prevalence of MS (15 cases per 100,000 people) compared to other Gulf countries, understanding the psychological, cognitive, and social ...
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback